Solventum Corporation $SOLV Stake Lifted by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in shares of Solventum Corporation (NYSE:SOLV) by 80.1% during the first quarter, Holdings Channel.com reports. The fund owned 36,307 shares of the company’s stock after purchasing an additional 16,150 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Solventum were worth $2,371,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SOLV. Hilltop National Bank boosted its stake in Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares in the last quarter. CrossGen Wealth LLC acquired a new position in shares of Solventum during the 4th quarter valued at $25,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Solventum in the 3rd quarter worth $25,000. JNBA Financial Advisors raised its stake in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after buying an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new stake in shares of Solventum in the second quarter valued at $28,000.

Solventum Price Performance

NYSE SOLV opened at $77.87 on Tuesday. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The business’s fifty day moving average is $75.43 and its two-hundred day moving average is $74.43. The stock has a market capitalization of $13.49 billion, a P/E ratio of 12.54, a P/E/G ratio of 1.21 and a beta of 0.66. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue was down 3.0% compared to the same quarter last year. During the same period last year, the company posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Stifel Nicolaus decreased their target price on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Piper Sandler dropped their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Wedbush assumed coverage on shares of Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target for the company. KeyCorp raised their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Rothschild & Co Redburn assumed coverage on shares of Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $83.73.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.